Stocks · News reference
Galmed Pharmaceuticals shares are trading higher after the company's subsidiary Colospan announced the completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment platform.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 2:07 PM
- Checked
- Aug 19, 2026, 2:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Galmed Pharma’s Subsidiary Colospan Completes Feasibility Study Supporting Development Of Intraoperative Colon Tissue Quality Assessment Platform
The prospective, single-arm study enrolled 32 colorectal cancer patients at three leading clinical centers in Israel. The primary objective was to demonstrate feasibility of intraoperative quantitative measurement of
Read original at benzingaTrading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Read original at benzinga